Citius Pharmaceuticals-Orlando Lunch 6/24/2024
Schedule
Mon Jun 24 2024 at 12:00 pm to 01:30 pm
Location
Eddie V's Prime Seafood | Orlando, FL
About this Event
*Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Monday, June 24, 2024
Eddie V's Prime Seafood<h4>7488 West Sand Lake Road</h4><h4>Orlando, FL 32819</h4>
Promptly at 12:00 PM
Join Citius Pharmaceuticals, Inc. in this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience.
We hope you can join our presentation
About Citius Pharmaceuticals, Inc.
Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates. Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, is enrolling patients in a Phase 3 Pivotal superiority trial and was granted Fast Track designation by the FDA. Citius Pharma is preparing to resubmit the Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in CTCL, in early 2024, and announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, at the end of March 2023, Citius Pharma completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
In the News
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Presentation Format:
12:00 p.m. to 1:30 p.m. - Presentation and Lunch
Contact:
Raymond Oliver
CEO, Bear Creek Capital
321-439-2120
Where is it happening?
Eddie V's Prime Seafood, 7488 West Sand Lake Road, Orlando, United StatesEvent Location & Nearby Stays:
USD 0.00
